Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) di...
| Metric Name | Value | Trend | |
|---|---|---|---|
| Dividend Yield | 0.0% | ||
| P/E Ratio | 24.5x | ||
| Revenue | 661.8 M | ||
| Net Income to Company | 73.865 M |
| SUPN | Peers | Sector | |
|---|---|---|---|
Market Cap | 1.81 B | 1.4 B | 64.805 M |
Price % of 52 Week High | 80.4% | 58.9% | 62.2% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | -0.3% | 8.4% | -0.7% |
1 Year Price Total Return | -5.0% | -4.8% | -11.5% |
Beta (5 Year) | 0.84 | 0.83 | 0.64 |
| (presentment in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 667 | 608 | 662 | 164 | 174 |
| Operating Income | 46 | 13 | 61 | 19 | 20 |
| Net Profit | 61 | 1.32 | 74 | 1.18 | 15 |
| Diluted EPS | 1.04 | 0.020 | 1.32 | 0.018 | 0.27 |
| EBITDA | 131 | 98 | 142 | 41 | 38 |
| Balance Sheet | |||||
| Cash & ST Invest. | 461 | 255 | 454 | 255 | 454 |
| Current Assets | 734 | 493 | 686 | 493 | 686 |
| Total Assets | 1,703 | 1,278 | 1,368 | 1,278 | 1,368 |
| Current Liabilities | 688 | 290 | 292 | 290 | 292 |
| Total Liabilities | 816 | 356 | 332 | 356 | 332 |
| Total Equity | 886 | 922 | 1,036 | 922 | 1,036 |
| Total Debt | 451 | 42 | 34 | 42 | 34 |
| Cash Flow Statement | |||||
| Cash Flow Operations | 117 | 111 | 172 | 45 | 44 |
| Cash From Investing | (217) | 269 | (190) | (66) | (13) |
| Cash From Financing | (10) | (398) | 12 | 1.09 | 5.89 |
| Free Cash Flow | 116 | 111 | 171 | 45 | 44 |